0HFR Stock Chart & Stats
$3.13
-$0.06(-2.42%)
At close: 4:00 PM EDT
$3.13
-$0.06(-2.42%)
Day’s Range― - ―
52-Week Range$2.27 - $10.46
Previous CloseN/A
Volume2.95K
Average Volume (3M)11.95K
Market Cap
$277.16M
Enterprise Value$122.28
Total Cash (Recent Filing)$118.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding92,696,840
10 Day Avg. Volume12,107
30 Day Avg. Volume11,954
Financial Highlights & Ratios
PEG Ratio-4.29
Price to Book (P/B)8.00
Price to Sales (P/S)0.00
P/FCF Ratio-19.44
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$776.00M
Bulls Say, Bears Say
Bulls Say
Financial ResourcesAnavex maintains sufficient cash resources to support operations at the current burn rate, supporting continuation of clinical development without added financing pressure.
Safety ProfileClinical studies reported no significant safety concerns for blarcamesine, including absence of amyloid-related imaging abnormalities, supporting a favorable tolerability profile.
Scientific Validation And VisibilityPlanned scientific presentations and peer-reviewed publications of trial findings will increase awareness and provide independent validation of blarcamesine's clinical effects.
Bears Say
Clinical And Financing RisksKey risks include the possibility of negative clinical results, failure to obtain approvals, challenges launching the drug commercially, setbacks with other candidates, and potential shareholder dilution.
European Approval DelayThe withdrawal of the marketing application for blarcamesine in Europe creates a delay that increases uncertainty around the program's approval prospects and commercial rollout in that market.
Regulatory RequirementsRegulators may require additional clinical studies before granting approval, which could expand development timelines and raise program costs.
Anavex Life Sciences News
0HFR FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest share price was $2.27 and its highest was $10.46 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $277.16M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is Nov 30, 2026 which is in 91 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Aug 25, 2026. The company reported -$0.08 earnings per share for the quarter.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Overvalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 92,696,840 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.08 in its last earnings report. Following the earnings report the stock price went up 13.482%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Currently, no hedge funds are holding shares in GB:0HFR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Anavex Life Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-79.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.29%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Anavex Life Sciences
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Technical Analysis
Galectin Therapeutics
―
Rocket Pharmaceuticals
―
Cellectis SA
―
Autolus Therapeutics
―
PepGen Inc.
―